View in EDS

Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial.

Saved in:
Bibliographic Details
Title: Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial.
Authors: Juric D; Mass General Cancer Center, Department of Medicine, Harvard Medical School, Boston, USA. Electronic address: Juric.Dejan@mgh.harvard.edu., Rugo HS; Department of Medicine (Hematology/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA., Reising A; Novartis Pharmaceuticals Corporation, East Hanover, USA., Vervier K; Novartis Pharma AG, Basel, Switzerland., Ma C; Novartis Pharmaceuticals Corporation, East Hanover, USA., Ciruelos EM; Medical Oncology, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain., Loibl S; Medicine and Research, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany., Singer CF; Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria., Sohn J; Yonsei Cancer Center, Seoul, Republic of Korea., Campone M; Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France., Conte P; S Camillo Hospital IRCCS, Lido of Venice, Venice, Italy., Iwata H; Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan., Ghaznawi F; Novartis Pharmaceuticals Corporation, East Hanover, USA., Miller M; Novartis Pharmaceuticals Corporation, East Hanover, USA., Taran T; Novartis Pharma AG, Basel, Switzerland., Su F; Novartis Pharmaceuticals Corporation, East Hanover, USA., André F; Medical Oncology, Institut Gustave Roussy, Villejuif, France.
Source: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2026 Apr 11. Date of Electronic Publication: 2026 Apr 11.
Publication Type: Journal Article
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41967638
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Juric+D%22">Juric D</searchLink>; Mass General Cancer Center, Department of Medicine, Harvard Medical School, Boston, USA. Electronic address: Juric.Dejan@mgh.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Rugo+HS%22">Rugo HS</searchLink>; Department of Medicine (Hematology/Oncology), University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, USA.<br /><searchLink fieldCode="AU" term="%22Reising+A%22">Reising A</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, USA.<br /><searchLink fieldCode="AU" term="%22Vervier+K%22">Vervier K</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Ma+C%22">Ma C</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, USA.<br /><searchLink fieldCode="AU" term="%22Ciruelos+EM%22">Ciruelos EM</searchLink>; Medical Oncology, Breast Cancer Unit, Hospital Universitario 12 de Octubre, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Loibl+S%22">Loibl S</searchLink>; Medicine and Research, German Breast Group, GBG Forschungs GmbH, Neu-Isenburg, Germany.<br /><searchLink fieldCode="AU" term="%22Singer+CF%22">Singer CF</searchLink>; Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.<br /><searchLink fieldCode="AU" term="%22Sohn+J%22">Sohn J</searchLink>; Yonsei Cancer Center, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Campone+M%22">Campone M</searchLink>; Oncology, Institut de Cancérologie de l'Ouest, Saint Herblain, France.<br /><searchLink fieldCode="AU" term="%22Conte+P%22">Conte P</searchLink>; S Camillo Hospital IRCCS, Lido of Venice, Venice, Italy.<br /><searchLink fieldCode="AU" term="%22Iwata+H%22">Iwata H</searchLink>; Breast Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.<br /><searchLink fieldCode="AU" term="%22Ghaznawi+F%22">Ghaznawi F</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, USA.<br /><searchLink fieldCode="AU" term="%22Miller+M%22">Miller M</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, USA.<br /><searchLink fieldCode="AU" term="%22Taran+T%22">Taran T</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Su+F%22">Su F</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, USA.<br /><searchLink fieldCode="AU" term="%22André+F%22">André F</searchLink>; Medical Oncology, Institut Gustave Roussy, Villejuif, France.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229007735%22">Annals of oncology : official journal of the European Society for Medical Oncology</searchLink> [Ann Oncol] 2026 Apr 11. <i>Date of Electronic Publication: </i>2026 Apr 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9007735 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1569-8041 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209237534%22">09237534 </searchLink><i>NLM ISO Abbreviation: </i>Ann Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41967638
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2026.04.003
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Juric D
      – PersonEntity:
          Name:
            NameFull: Rugo HS
      – PersonEntity:
          Name:
            NameFull: Reising A
      – PersonEntity:
          Name:
            NameFull: Vervier K
      – PersonEntity:
          Name:
            NameFull: Ma C
      – PersonEntity:
          Name:
            NameFull: Ciruelos EM
      – PersonEntity:
          Name:
            NameFull: Loibl S
      – PersonEntity:
          Name:
            NameFull: Singer CF
      – PersonEntity:
          Name:
            NameFull: Sohn J
      – PersonEntity:
          Name:
            NameFull: Campone M
      – PersonEntity:
          Name:
            NameFull: Conte P
      – PersonEntity:
          Name:
            NameFull: Iwata H
      – PersonEntity:
          Name:
            NameFull: Ghaznawi F
      – PersonEntity:
          Name:
            NameFull: Miller M
      – PersonEntity:
          Name:
            NameFull: Taran T
      – PersonEntity:
          Name:
            NameFull: Su F
      – PersonEntity:
          Name:
            NameFull: André F
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 11
              M: 04
              Text: 2026 Apr 11
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1569-8041
          Titles:
            – TitleFull: Annals of oncology : official journal of the European Society for Medical Oncology
              Type: main
ResultId 1